Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01425 | NH2-PEG4-VC-PAB-DMEA-SN38 | |
| NH2-PEG4-VC-PAB-DMEA-SN38 is a sortase-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-01432 | Cys-MC-MMAF | 1160590-05-5 |
| Cys-MC-MMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody that is conjugated to microtubule MMAF destruction via a maleimidocaproyl linker. It has antitumor effects on two tumor mouse models (H1975 and MDA-MB-361-DYT2). | Inquiry | |
| BADC-01433 | N-Ac-Cys-LND1025 | |
| N-Ac-Cys-LND1025 is an ADC metabolite used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-01434 | Cys-MC-VC-PAB-MMAE | |
| Cys-MC-VC-PAB-MMAE is an ADC metabolite used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-01435 | N-Ac-Cys-MC-VC-PAB-MMAE | 1628933-80-1 |
| N-Ac-Cys-MC-VC-PAB-MMAE is an ADC metabolite used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-01450 | MCC-DM1 | 1100692-14-5 |
| MCC-DM1 is a drug-linker conjugate for ADC synthesis, such as Anti-CD22-MCC-DM1. | Inquiry | |
| BADC-01451 | MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT | 2378428-19-2 |
| MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT, a camptothecin-linker compound, is part of a drug-linker conjugate for ADC. For details, please refer to Example 4-1 in patent document WO2019195665A1. | Inquiry | |
| BADC-01452 | MC-SN38 | 1473403-87-0 |
| MC-SN38 is a highly efficacious antineoplastic compound utilized within the realm of biomedicine and emerges as a derivative hailing from the natural entity SN-38. Distinguished by its formidable cytotoxic potential against malignant cells, MC-SN38 finds widespread application in combating an assortment of solid neoplasms encompassing colorectal, gastric, and pancreatic origins. | Inquiry | |
| BADC-01453 | Thalidomide-NH-PEG7 | 2641838-98-2 |
| Thalidomide-NH-PEG7 is an E3 ligase ligand-linker conjugate used in the synthesis of ADCs. Thalidomide-NH-PEG7 can be linked to protein ligands through a linker to form PROTAC iRucaparib-AP6 (a highly specific PARP1 degrader). | Inquiry | |
| BADC-01455 | Modified MMAF-C5-COOH | 1404071-65-3 |
| Modified MMAF-C5-COOH is a drug-linker conjugate for ADC. | Inquiry | |
| BADC-01457 | CCK2R Ligand-Linker Conjugates 1 | 1452145-13-9 |
| CCK2R Ligand-Linker Conjugates 1 are ligand-linker conjugates that bind to the cytotoxic microtubule inhibitors Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. | Inquiry | |
| BADC-01458 | SuO-Val-Cit-PAB-MMAE | |
| SuO-Val-Cit-PAB-MMAE is part of an antibody drug conjugate (drug-linker conjugate for ADC). Consists of the peptide SuO-Val-Cit-PAB linked to the antimitotic agent MMAE, a tubulin inhibitor. | Inquiry | |
| BADC-01459 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 |
| MC-betaglucuronide-MMAE-1 is part of an antibody-drug conjugate consisting of tubulin polymerization inhibitor MMAE and degradable ADC linker MC-betaglucuronide. | Inquiry | |
| BADC-01460 | DBM-MMAF | 1810001-93-4 |
| DBM-MMAF is composed of linker DBM and toxic molecule MMAF, which can be used to prepare antibody-conjugated drugs. | Inquiry | |
| BADC-01461 | MC-betaglucuronide-MMAE-2 | |
| MC-betaglucuronide-MMAE-2 is part of an antibody-drug conjugate consisting of tubulin polymerization inhibitor MMAE and degradable ADC linker MC-betaglucuronide. | Inquiry | |
| BADC-01462 | N3-PEG4-DYKDDDD-Doxorubicin | |
| N3-PEG4-DYKDDDD-Doxorubicin is part of an antibody drug conjugate consisting of the anthracycline antibiotic Doxorubicin and a degradable ADC linker N3-PEG4-DYKDDDD. | Inquiry | |
| BADC-01463 | Azide-PEG4-VC-PAB-Doxorubicin | |
| Azide-PEG4-VC-PAB-Doxorubicin is composed of linker Azide-PEG4-VC-PAB and toxic molecule Doxorubicin, which can be used to prepare antibody-conjugated drugs. | Inquiry | |
| BADC-01464 | N3-PEG4-YPYDVPDYA-Doxorubicin | |
| N3-PEG4-YPYDVPDYA-Doxorubicin is part of an antibody drug conjugate consisting of the anthracycline antibiotic Doxorubicin and the degradable ADC linker N3-PEG4-YPYDVPDYA. | Inquiry | |
| BADC-01465 | MB-VC-MGBA | 932744-62-2 |
| MB-VC-MGBA is a part of antibody drug conjugates, which is formed by linking DNA alkylating agent MGBA and ADC linker MB-VC. | Inquiry | |
| BADC-01466 | Desmethyl Vc-seco-DUBA | |
| Desmethyl Vc-seco-DUBA is an innovative biomedical product used in the treatment of various diseases. It exhibits potent anti-inflammatory properties, making it effective in managing chronic inflammation associated with autoimmune disorders. Its precise mechanism of action involves specifically targeting the overactive immune response and modulating inflammatory pathways. By alleviating inflammation, Desmethyl Vc-seco-DUBA offers promising therapeutic potential in conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. | Inquiry |
